# Dose-finding Study of MCI-196

> **NCT01814904** · PHASE3 · TERMINATED · sponsor: **Tanabe Pharma Corporation** · enrollment: 10 (actual)

## Conditions studied

- Chronic Kidney Disease
- Dialysis
- Hyperphosphatemia
- Paediatric

## Interventions

- **DRUG:** colestilan-L
- **DRUG:** colestilan-M
- **DRUG:** colestilan-H
- **DRUG:** CBPB

## Key facts

- **NCT ID:** NCT01814904
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** This study has been terminated because of insufficient patient recruitment.
- **Last updated:** 2015-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814904, "Dose-finding Study of MCI-196". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01814904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*